Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

CDXS - Codexis, Inc. Latest News | Finranks

Home

CDXS

C

Codexis, Inc. (CDXS)

NMS – Real Time Price. Currency in USD

1.58

-0.08 (-4.82%)

At close: Mar 27, 2026, 4:00 PM EDT

1.57

-0.01 (-0.63%)

After-hours: Mar 27, 2026, 7:32 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.

Codexis Achieves ISO 9001:2015 Certification

Codexis Achieves ISO 9001:2015 Certification

REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The official certification reflects Codexis's dedication to delivering manufacturing excellence by applying a high standard of quality assurance throughout all of its processes, including research and development, product manufacturing and testing, delivery, support, and customer service.

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), today announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform.